Total Payments
$13,612
2024 Payments
$1,242
Companies
29
Transactions
605
Medicare Patients
1,300
Medicare Billing
$399,262
Payment Breakdown by Category
Food & Beverage$11,824 (86.9%)
Consulting$1,480 (10.9%)
Education$204.80 (1.5%)
Other$102.98 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,824 | 585 | 86.9% |
| Consulting Fee | $1,480 | 5 | 10.9% |
| Education | $204.80 | 10 | 1.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $102.98 | 5 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $3,917 | 196 | $0 (2024) |
| ViiV Healthcare Company | $2,396 | 115 | $0 (2024) |
| Janssen Biotech, Inc. | $1,349 | 76 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,063 | 56 | $0 (2024) |
| Melinta Therapeutics, LLC | $735.27 | 35 | $0 (2024) |
| Theravance Biopharma, Inc. | $607.24 | 11 | $0 (2018) |
| ABBVIE INC. | $516.31 | 22 | $0 (2024) |
| Becton, Dickinson and Company | $426.67 | 1 | $0 (2022) |
| Napo Pharmaceuticals Inc | $405.90 | 17 | $0 (2024) |
| Pacira Pharmaceuticals Incorporated | $293.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,242 | 60 | Gilead Sciences, Inc. ($417.01) |
| 2023 | $1,474 | 64 | ViiV Healthcare Company ($490.10) |
| 2022 | $1,928 | 70 | ViiV Healthcare Company ($519.68) |
| 2021 | $1,723 | 87 | Gilead Sciences, Inc. ($562.63) |
| 2020 | $1,410 | 67 | Gilead Sciences, Inc. ($602.14) |
| 2019 | $1,652 | 88 | Gilead Sciences, Inc. ($499.32) |
| 2018 | $2,158 | 75 | Theravance Biopharma, Inc. ($477.59) |
| 2017 | $2,024 | 94 | Gilead Sciences Inc ($510.82) |
All Payment Transactions
605 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.89 | General |
| 10/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.05 | General |
| 10/15/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.40 | General |
| 09/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.59 | General |
| 09/19/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.29 | General |
| Category: ANTIBIOTIC | ||||||
| 09/17/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $31.75 | General |
| Category: HIV | ||||||
| 09/17/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $2.50 | General |
| Category: HIV | ||||||
| 09/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.46 | General |
| 08/27/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $33.27 | General |
| Category: HIV | ||||||
| 08/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.32 | General |
| 08/15/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $33.26 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.62 | General |
| 08/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $5.54 | General |
| Category: HIV | ||||||
| 08/07/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $5.36 | General |
| 08/05/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: HIV | ||||||
| 08/05/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Orbactiv | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: ANTIFUNGALS | ||||||
| 08/05/2024 | ViiV Healthcare Company | RUKOBIA (Drug) | Food and Beverage | In-kind items and services | $4.84 | General |
| Category: HIV | ||||||
| 07/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.32 | General |
| 07/23/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: HIV | ||||||
| 07/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.35 | General |
| 06/21/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $34.74 | General |
| Category: HIV | ||||||
| 06/20/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: HIV | ||||||
| 06/20/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $8.80 | General |
| Category: HIV | ||||||
| 06/07/2024 | ABBVIE INC. | TEFLARO (Drug), AVYCAZ, DALVANCE | Food and Beverage | In-kind items and services | $34.35 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 250 | 957 | $169,151 | $82,785 |
| 2022 | 4 | 309 | 760 | $169,812 | $77,190 |
| 2021 | 7 | 289 | 1,012 | $213,925 | $103,946 |
| 2020 | 8 | 452 | 1,345 | $277,735 | $135,341 |
Total Patients
1,300
Total Services
4,074
Medicare Billing
$399,262
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 70 | 537 | $104,715 | $53,394 | 51.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 72 | 87 | $25,404 | $12,592 | 49.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 81 | $18,792 | $10,400 | 55.3% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 59 | 232 | $16,240 | $5,866 | 36.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 20 | $4,000 | $533.15 | 13.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 88 | 484 | $94,380 | $41,465 | 43.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 97 | 105 | $30,660 | $17,096 | 55.8% |
| 99358 | Extended patient service without direct patient contact, first hour | Facility | 2022 | 93 | 102 | $28,764 | $9,355 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 31 | 69 | $16,008 | $9,274 | 57.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 81 | 579 | $112,905 | $51,577 | 45.7% |
| 99310 | Subsequent nursing facility visit, typically 35 minutes per day | Facility | 2021 | 12 | 142 | $25,844 | $16,462 | 63.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 75 | 94 | $27,448 | $16,091 | 58.6% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2021 | 66 | 92 | $25,944 | $8,861 | 34.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 30 | 59 | $13,688 | $8,826 | 64.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 12 | 24 | $3,696 | $1,489 | 40.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 13 | 22 | $4,400 | $638.71 | 14.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 131 | 769 | $149,955 | $69,267 | 46.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 122 | 134 | $39,128 | $23,701 | 60.6% |
| 99310 | Subsequent nursing facility visit, typically 35 minutes per day | Facility | 2020 | 18 | 121 | $22,022 | $13,998 | 63.6% |
| 99358 | Prolonged patient service without direct patient contact first hour | Facility | 2020 | 95 | 103 | $29,046 | $9,989 | 34.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 34 | 64 | $14,848 | $7,084 | 47.7% |
| 99309 | Subsequent nursing facility visit, typically 25 minutes per day | Facility | 2020 | 13 | 61 | $8,540 | $4,805 | 56.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 24 | 72 | $11,088 | $4,512 | 40.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 21 | $3,108 | $1,985 | 63.9% |
About Dr. Mitchell Weinstein, M.D
Dr. Mitchell Weinstein, M.D is a Infectious Disease healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447270475.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Weinstein, M.D has received a total of $13,612 in payments from pharmaceutical and medical device companies, with $1,242 received in 2024. These payments were reported across 605 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($11,824).
As a Medicare-enrolled provider, Weinstein has provided services to 1,300 Medicare beneficiaries, totaling 4,074 services with total Medicare billing of $399,262. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Chicago, IL
- Active Since 07/20/2006
- Last Updated 02/18/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1447270475
Products in Payments
- DOVATO (Drug) $942.74
- SYMTUZA (Drug) $781.12
- CABENUVA (Biological) $420.80
- Mytesi (Drug) $405.90
- APRETUDE (Biological) $391.90
- PIFELTRO (Drug) $387.16
- Symtuza (Drug) $370.79
- Vabomere (Drug) $367.28
- ISENTRESS (Drug) $334.12
- PREZCOBIX (Drug) $293.59
- EXPAREL (Drug) $293.00
- RUKOBIA (Drug) $279.07
- ZERBAXA (Drug) $271.80
- TRIUMEQ (Drug) $269.81
- Mavyret (Drug) $245.18
- NUZYRA (Drug) $229.67
- AVYCAZ (Drug) $203.30
- VIBATIV (Drug) $200.24
- Fetroja (Drug) $168.78
- EGRIFTA (Drug) $163.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Chicago
Frank Palella, Md, MD
Infectious Disease — Payments: $1.3M
Infectious Disease $1.3M
Dr. Babafemi Taiwo, Md, MD
Infectious Disease — Payments: $390,320
Infectious Disease $390,320
Catherine Creticos, Md, MD
Infectious Disease — Payments: $312,981
Infectious Disease $312,981
Dr. Nancy Glick, M.d, M.D
Infectious Disease — Payments: $259,059
Infectious Disease $259,059
Dr. James Sullivan, Md, MD
Infectious Disease — Payments: $162,355
Infectious Disease $162,355
Kathleen Mullane
Infectious Disease — Payments: $156,063
Infectious Disease $156,063